American Psychiatric Association

The American Psychiatric Association is presented not as the operator of psychedelic trials or the source of a formal policy shift, but as an influential professional institution whose former leaders and members became visible in the movement to reassess psychedelic therapy. Its presence marks a change in the treatment’s standing: practices once pushed outside sanctioned medicine were beginning to attract attention from psychiatry’s establishment, even as questions about evidence, safety, and medical control remained unresolved.

Institutional Visibility in the Research Revival

The Association’s former presidents figured prominently in the public reception of the NYU and Johns Hopkins psilocybin cancer studies. When the results appeared together in a special issue of the Journal of Psychopharmacology in December 2016, nearly a dozen commentaries from prominent mental-health voices accompanied them, including contributions from two former presidents of the American Psychiatric Association. Their presence helped show how far psychedelic therapy had moved from the margins, but it did not amount to proof that the treatment was already accepted as routine psychiatric care.

The trials themselves were small, with eighty subjects in all, and the results needed replication at larger scale before regulators would consider rescheduling psilocybin and approving the treatment. Still, the findings drew cautious support and requests for further research. The book describes this response as a moment when psychedelic therapy had become respectable again, or nearly so. That qualification matters: professional recognition was increasing, while clinical authorization and the evidentiary standards required for it remained ahead.

Former Leaders and Personal Experience

The Association also appears as a setting in which personal history and professional authority met. At its 2015 meeting, a videotaped interview with Ram Dass was shown in which Paul Summergrad, a former president, spoke publicly about taking LSD in college and described the experience as formative in his intellectual development. His account placed a youthful psychedelic experience within the biography of a senior psychiatric figure rather than treating such experience only as an external threat to professional medicine.

Rick Doblin interpreted the familiarity of institutional leaders with psychedelics as part of Timothy Leary’s legacy. Doblin argued that, despite researchers’ criticism of Leary’s conduct and its role in derailing the first wave of research, there would be no second wave if Leary had not introduced a generation to psychedelics. The Summergrad example gave that claim a concrete institutional dimension: earlier personal exposure could persist into the professional world that later judged the treatment. The book also notes that Jeffrey Lieberman, another former president of the Association, had written about insights gained through youthful LSD experiments.

A Difficult Fit with Psychiatric Method

The renewed attention did not remove the methodological problems that psychedelic treatment posed for psychiatry. Participants and guides can often tell whether a session involved psilocybin or a placebo, making conventional blinding difficult. Researchers also face the problem of separating a drug’s effects from set and setting, the therapist’s presence, and the volunteer’s expectations. These factors complicate the effort to isolate a single variable, a central expectation of modern drug trials.

The treatment model itself challenges conventional psychiatric arrangements. In the account of psychedelic therapy’s emergence, a high-dose session intended to produce a conversion-like experience contrasted with the more familiar pattern of prolonged weekly treatment. The therapist’s role and the patient’s position therefore had to be reconsidered alongside the drug’s action. Charles Grob described the model as applied mysticism, a characterization that exposed an uncomfortable boundary for a profession increasingly committed to biochemical accounts of the mind. The controversy was not simply whether a compound could reduce symptoms; it also concerned how psychiatry could evaluate an experience whose meaning, context, and therapeutic relationship appeared inseparable from its effects.

Recognition, Medicalization, and Unsettled Boundaries

The book links the Association’s growing visibility to a broader question: whether renewed acceptance should mean bringing psychedelics under medical authority alone. At a later conference, the former heads of the Association and the National Institute of Mental Health appeared together on a panel about the future of psychedelic psychiatry. Their presence was read by the audience as a sign that the mental-health establishment was recognizing the field. Yet the discussion also underscored the need for safety, rigor, and protection against reputational damage; the promise of a new treatment did not excuse careless research or practice.

That institutional pathway remained contested. Bob Jesse worried that making medicalization the only legitimate route would narrow the possible uses of psychedelics. Rick Doblin hoped for broader cultural acceptance, while other advocates imagined carefully supervised settings beyond conventional clinical treatment. Their proposals included trained guides, longer-term communities of practice, and opportunities for people seeking mental-health support, spiritual exploration, or personal development. The book does not present the Association as having adopted these broader ambitions. Rather, it places the organization within a debate over who may administer psychedelics, what purposes count as legitimate, and whether a powerful experience can be adequately understood as a drug treatment isolated from its social and interpretive setting.